Concentra Group Holdings Parent vs Progyny
CON and PGNY side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CON and PGNY compare
Concentra Group Holdings Parent is the larger company, worth 2.3 times as much as Progyny ($5.1B against $2.2B).
On earnings, Concentra Group Holdings Parent is cheaper: it trades at 26.2× trailing earnings, against 31.7× for Progyny.
Concentra Group Holdings Parent grew revenue faster over the last twelve months (14.0% versus 5.5% for Progyny).
Concentra Group Holdings Parent keeps more of each dollar of sales as profit, with a net margin of 8.7% compared with 6.0% at Progyny.
Concentra Group Holdings Parent pays a dividend yielding 0.62%; Progyny does not pay one.
Progyny scores higher on the StockData Score (19 against 11 for Concentra Group Holdings Parent), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CON | PGNY |
|---|---|---|
| Size and price | ||
| Market cap | $5.1B | $2.2B |
| Share price | $40.38 | $29.19 |
| Change, 1 year | 101% | 52.9% |
| Change, 5 years | – | −53.6% |
| Beta (5Y) | 0.54 | 1.11 |
| Employees | 13K | 856 |
| StockData Score | ||
| Total score | 11 | 19 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 3 | 5 (better) |
| Performance score | 3 | 5 (better) |
| Health score | 2 | 6 (better) |
| Dividend score | 3 (better) | 0 |
| Valuation | ||
| P/E | 26.2× (better) | 31.7× |
| P/S | 2.3× | 1.7× (better) |
| P/B | 10.8× | 4.9× (better) |
| EV/EBITDA | 14.5× (better) | 17.0× |
| P/FCF | 19.3× | 12.6× (better) |
| PEG | – | 1.08 |
| FCF yield | 5.2% | 8.0% (better) |
| Fair value | $32.95 | $35.74 |
| Margin of safety | −22.5% | 18.3% (better) |
| Growth | ||
| Revenue growth (TTM) | 14.0% (better) | 5.5% |
| Revenue growth, 5Y average | – | 30.2% |
| Net income growth (TTM) | 33.1% | 48.0% (better) |
| EPS growth (TTM) | 29.4% | 55.9% (better) |
| EPS growth, 5Y average | – | 6.7% |
| Profitability | ||
| Gross margin | 29.3% (better) | 24.6% |
| Operating margin | 16.4% (better) | 8.6% |
| Net margin | 8.7% (better) | 6.0% |
| FCF margin | 11.7% | 13.6% (better) |
| Return on equity | 48.5% (better) | 16.2% |
| Return on invested capital | 15.1% | 34.5% (better) |
| Financial health | ||
| Debt / equity | 3.30 (better) | 0.00 |
| Net debt / EBITDA | 3.11 | – |
| Current ratio | 1.38 | 2.14 (better) |
| Altman Z-score | 2.57 | 8.42 (better) |
| Piotroski F-score | 6 | 8 (better) |
| Dividends and buybacks | ||
| Dividend yield | 0.62% | – |
| Payout ratio | 16.1% | – |
| Years of dividend growth | 1 | – |
| Buyback yield | – | 10.3% |
| Shareholder yield | 0.62% | 10.3% (better) |
| Ownership | ||
| Held by institutions | 88.2% | 103% |
| Held by insiders | 10.8% | 2.7% |
| Insider net buying, 12 months | −$14.6M | −$643K (better) |
| Short interest, % of float | 3.2% | 6.8% |
Go deeper
- CON stock overview
- CON income statement
- CON valuation and score
- PGNY stock overview
- PGNY income statement
- PGNY valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.